Correlation of Anti-Phosphatidylserine/Prothrombin and Anti-Phosphatidylserine Antibodies with Pregnancy Outcomes

IF 2.5 3区医学 Q3 IMMUNOLOGY

American Journal of Reproductive Immunology Pub Date : 2024-07-03 DOI:10.1111/aji.13890

Junmiao Xiang, Yundong Pan, Ruru Bao, Zhuhua Cai

{"title":"Correlation of Anti-Phosphatidylserine/Prothrombin and Anti-Phosphatidylserine Antibodies with Pregnancy Outcomes","authors":"Junmiao Xiang, Yundong Pan, Ruru Bao, Zhuhua Cai","doi":"10.1111/aji.13890","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The objective of this study was to investigate the clinical relevance of anti-prothrombin antibodies (aPT) and anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in relation to pregnancy outcomes and coagulation parameters, as well as immune markers.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We retrospectively analyzed 477 pregnant women with experienced at least one spontaneous miscarriage who were tested for aPT and aPS/PT antibodies, and compared their clinical characteristics, coagulation indicators, immune biomarkers, and pregnancy outcomes to assess the diagnostic accuracy of these antibodies.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We found that the aPT IgG and the aPS/PT IgM were independently associated with increased risk of pregnancy loss, with odds ratios (ORs) of 1.055 (95% confidence interval [CI]: 1.009–1.103, <i>p</i> = 0.017) and 1.041 (95% CI: 1.015–1.067, <i>p</i> = 0.002), respectively. Moreover, we found that the aPS/PT IgM had a higher diagnostic performance than the aPT IgG, as indicated by the AUC of 0.663 and 0.593, respectively. The pregnancy loss rate was positively correlated with the level of aPS/PT IgM, while the aPT IgG is not. We also found that in the pregnancy loss group, aPT IgG showed negative correlations with prothrombin time (PT); aPS/PT IgM showed positive correlations with aPS/PT IgG. However, none of aPT IgG, aPT IgM, aPS/PT IgM, or aPS/PT IgG was related to other adverse pregnancy outcomes, such as preterm delivery, fetal growth restriction (FGR), or preeclampsia (PE).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our findings suggest that aPT IgG and aPS/PT IgM are independent risk factors for pregnancy loss, especially aPS/PT IgM, which has a positive linear correlation with pregnancy loss.</p>\n </section>\n </div>","PeriodicalId":7665,"journal":{"name":"American Journal of Reproductive Immunology","volume":"92 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aji.13890","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Reproductive Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aji.13890","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The objective of this study was to investigate the clinical relevance of anti-prothrombin antibodies (aPT) and anti-phosphatidylserine/prothrombin antibodies (aPS/PT) in relation to pregnancy outcomes and coagulation parameters, as well as immune markers.

Methods

We retrospectively analyzed 477 pregnant women with experienced at least one spontaneous miscarriage who were tested for aPT and aPS/PT antibodies, and compared their clinical characteristics, coagulation indicators, immune biomarkers, and pregnancy outcomes to assess the diagnostic accuracy of these antibodies.

Results

We found that the aPT IgG and the aPS/PT IgM were independently associated with increased risk of pregnancy loss, with odds ratios (ORs) of 1.055 (95% confidence interval [CI]: 1.009–1.103, p = 0.017) and 1.041 (95% CI: 1.015–1.067, p = 0.002), respectively. Moreover, we found that the aPS/PT IgM had a higher diagnostic performance than the aPT IgG, as indicated by the AUC of 0.663 and 0.593, respectively. The pregnancy loss rate was positively correlated with the level of aPS/PT IgM, while the aPT IgG is not. We also found that in the pregnancy loss group, aPT IgG showed negative correlations with prothrombin time (PT); aPS/PT IgM showed positive correlations with aPS/PT IgG. However, none of aPT IgG, aPT IgM, aPS/PT IgM, or aPS/PT IgG was related to other adverse pregnancy outcomes, such as preterm delivery, fetal growth restriction (FGR), or preeclampsia (PE).

Conclusion

Our findings suggest that aPT IgG and aPS/PT IgM are independent risk factors for pregnancy loss, especially aPS/PT IgM, which has a positive linear correlation with pregnancy loss.

Abstract Image

查看原文本刊更多论文

抗磷脂酰丝氨酸/凝血酶原和抗磷脂酰丝氨酸抗体与妊娠结局的相关性。

研究背景本研究旨在探讨抗凝血酶原抗体（aPT）和抗磷脂酰丝氨酸/凝血酶原抗体（aPS/PT）与妊娠结局、凝血指标及免疫标志物的临床相关性：我们对477名至少经历过一次自然流产的孕妇进行了aPT和aPS/PT抗体检测，并比较了她们的临床特征、凝血指标、免疫生物标志物和妊娠结局，以评估这些抗体的诊断准确性：结果：我们发现 aPT IgG 和 aPS/PT IgM 与妊娠失败风险增加独立相关，其几率比（ORs）分别为 1.055（95% 置信区间 [CI]：1.009-1.103，p = 0.017）和 1.041（95% 置信区间 [CI]：1.015-1.067，p = 0.002）。此外，我们发现 aPS/PT IgM 的 AUC 分别为 0.663 和 0.593，诊断性能高于 aPT IgG。妊娠失败率与 aPS/PT IgM 水平呈正相关，而 aPT IgG 则不呈正相关。我们还发现，在妊娠损失组中，aPT IgG 与凝血酶原时间（PT）呈负相关；aPS/PT IgM 与 aPS/PT IgG 呈正相关。然而，aPT IgG、aPT IgM、aPS/PT IgM 或 aPS/PT IgG 均与其他不良妊娠结局无关，如早产、胎儿生长受限（FGR）或子痫前期（PE）：我们的研究结果表明，aPT IgG 和 aPS/PT IgM 是导致妊娠失败的独立风险因素，尤其是 aPS/PT IgM，它与妊娠失败呈正线性关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Reproductive Immunology 医学-免疫学

CiteScore

6.20

自引率

5.60%

发文量

314

审稿时长

2 months

期刊介绍： The American Journal of Reproductive Immunology is an international journal devoted to the presentation of current information in all areas relating to Reproductive Immunology. The journal is directed toward both the basic scientist and the clinician, covering the whole process of reproduction as affected by immunological processes. The journal covers a variety of subspecialty topics, including fertility immunology, pregnancy immunology, immunogenetics, mucosal immunology, immunocontraception, endometriosis, abortion, tumor immunology of the reproductive tract, autoantibodies, infectious disease of the reproductive tract, and technical news.